Skip to content

This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Theranostics Online Congresses - Join Medical Events.

Advancing Precision Oncology: Latest Updates on Innovation in Theranostics for Neuroendocrine Tumours and Beyond

Join leading experts at EANM 2025 for a symposium on SSTR-targeting theranostics in NETs. Explore clinical updates, expert views & learning resources. Register free.

Stay apprised of the field of Theranostics, reviewing radiopharmaceuticals for precision oncology therapy and diagnostics, with access to expert discussions, clinical trial updates, and practical learning resources. SSTR-Targeting Theranostics in NETs and Beyond: Milestones and New Frontiers.

Theranostics.online is the educational hub designed for oncologists, endocrinologists, nuclear medicine experts, gastroenterologists and clinical nurse specialists. We bring you access to expert discussions and educational resources dedicated to advancing theranostics in neuroendocrine tumour (NET) diagnosis and treatment, and beyond.

A multidisciplinary team including an oncologist and endocrinologist discussing a NETs case using theranostic data.

Register for free to unlock our full Theranostics library and resources to stay updated

Join leading experts at the European Association of Nuclear Medicine (EANM) Meeting, 2025, Barcelona, for a ground-breaking symposium

SSTR-Targeting Theranostics in NETs and Beyond: Milestones and New Frontiers

Headshot of Professor Ken Herrmann, M.D., MBA, Chair of the EANM Oncology & Theranostics Committee, who is hosting the theranostics symposium.

Professor Ken Herrmann M.D., MBA,
Nuclear Medicine, University Clinic Essen, Germany, and Chair of the EANM Oncology & Theranostics Committee will be hosting a session where we delve into the development and emerging clinical role of investigational 177Lu-edotreotide for treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs), explore its scientific origins and current evidence, and look toward future directions in SSTR-targeted therapies. The session will feature a number of renowned experts:

Date & Time: Sunday, October 5, 2025, from 13:15 to 14:45 (CEST)
Location: Room 114, EANM 2025 Congress venue (CCIB, Barcelona); with livestream available

For further information you can visit the EANM website.

The session will feature a number of renowned experts:

Headshot of Professor Ken Herrmann, M.D., MBA, Chair of the EANM Oncology & Theranostics Committee, who is hosting the theranostics symposium.

Prof. Ken Herrmann, M.D., MBA

Nuclear Medicine, University Clinic Essen, Germany

Headshot of symposium speaker Professor Vikas Prasad, M.D., PhD, an expert in Nuclear Medicine from the Mallinckrodt Institute of Radiology.

Prof. Vikas Prasad, M.D., PhD

Nuclear Medicine, Mallinckrodt Institute of Radiology, St. Louis, USA

¹⁷⁷Lu-edotreotide is still investigational.

“From concept to clinic: The Origins of ¹⁷⁷Lu-edotreotide in NETs”

Headshot of symposium speaker Dr. Rocío García-Carbonero, M.D., PhD, from the University Hospital 12 de Octubre in Madrid, Spain.

Dr. Rocío García-Carbonero, M.D., PhD

University Hospital 12 de Octubre, Madrid, Spain

¹⁷⁷Lu-edotreotide is still investigational.

“Translating evidence into practice: The role of ¹⁷⁷Lu-edotreotide in NETs”

Headshot of symposium speaker Professor Damian Wild, M.D., PhD, an expert from the University Hospital Basel, Switzerland.

Prof. Damian Wild, M.D., PhD

University Hospital Basel, Switzerland

¹⁷⁷Lu-edotreotide is still investigational.

“Exploring the future of the SSTR-targeting landscape”

Computer monitor displaying advanced SSTR-targeting theranostic imaging scans for a neuroendocrine tumour patient.

Neuroendocrine Tumours: The Theranostics Revolution

¹⁷⁷Lu radiopharmaceuticals are rapidly becoming a cornerstone in GEP-NET therapy. Explore how radiopharmaceuticals could shape their place in modern oncology on Theranostics.online

Hear more from Theranostics experts on how this field is
rapidly evolving:

Dr. Heloisa Soares, Medical Oncologist, discusses the unmet need in managing NETs, the rapidly evolving research base and how future guidelines for NETs may change with the upcoming theranostics developments.

Learn More

Prof. Damian Wild, Nuclear Medicine Specialist, discusses the important role of nuclear medicine physicians in multidisciplinary oncology tumour boards, and the future of dosimetry in clinical practice.

Learn More Hear More From Experts
A diverse team of healthcare professionals in discussion over a tablet, reviewing radiopharmaceutical trial data for NETs.

Translating Theranostics into Clinical Practice

Watch the on-demand symposium "How to Speak 'Theranostics' in NET: Translating Key Principles into Clinical Practice" presented earlier in the year at the European Neuroendocrine Tumor Society (ENETS) Meeting, 2025.

In this session, chaired by Dr. Capdevilla, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, the multidisciplinary expert panel explore how theranostics is applied in real world NET clinical practice.

Through case-based discussions, interactive exchanges, and forward-looking perspectives, this panel helps healthcare professionals:

  • Understand the language and principles of theranostics

  • See how molecular imaging and targeted radionuclide therapy fit into daily workflows

  • Gain insights into future theranostic developments

Register and access the full symposium replay.

Watch the Replay
A nuclear medicine expert presenting the latest findings in theranostics for oncology at a medical education seminar.

Learning Resources for HCPs

Practical Tools to Support Your Clinical Work and Sessions
Theranostics.online provides a growing library of resources to help you integrate theranostics into patient care:

Every resource is created to support oncologists, endocrinologists, nuclear medicine experts, gastroenterologists and clinical nurse specialists in advancing NET management.

This medical education site is sponsored by ITM Oncologics GmbH.

Explore More Learning Resources

Learning Library

A male doctor, a nuclear medicine specialist, carefully analysing a patient's theranostic imaging scan in a clinical setting.

Theranostics is redefining the way neuroendocrine tumours are diagnosed and treated. Register for free and join the growing community of healthcare professionals who use Theranostics.online to stay up-to-date, gain practical tools, and access the latest expert content.

Sign in now